12 results on '"Sokol MC"'
Search Results
2. The effects of copayments on medication adherence during the first two years of prescription drug treatment.
- Author
-
Kessler RC, Cantrell CR, Berglund P, and Sokol MC
- Published
- 2007
- Full Text
- View/download PDF
3. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
- Author
-
Stein MB, Cantrell CR, Sokol MC, Eaddy MT, and Shah MB
- Abstract
OBJECTIVES: This study evaluated adherence with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) among patients who newly initiated therapy for anxiety with or without comorbid depression; the study also quantified the health-related economic consequences of nonadherence. METHODS: A large managed care database was used to gather retrospective data for patients with anxiety disorders who had a prescription for an antidepressant between July 1, 2001, and December 31, 2002. The relationship between antidepressant adherence and medical resource utilization was assessed; the analysis controlled for age, gender, utilization of mental health specialty care, change in medication, whether the dosage was titrated, costs in the six months before the prescription for an antidepressant, and comorbid physical conditions. RESULTS: Of the 13,085 patients with anxiety diagnoses who met the criteria for study inclusion, 57 percent were nonadherent to antidepressant therapy at six months. Patients who received mental health specialty care were more likely than those who did not receive such care to be adherent to therapy (48.5 percent compared with 40.7 percent; p<.001). Those with dual diagnoses of anxiety and depression were more likely than those with anxiety alone to be adherent to therapy (46.8 percent compared with 40.2 percent; p<.001). Those with a coded diagnosis of posttraumatic stress disorder had the highest medical costs. Patients with anxiety and depression had significantly higher total costs than patients with anxiety alone. Adherent patients who did not have a change in medication or a titrated dosage had significantly lower medical costs than nonadherent patients; however, total costs (medical plus pharmacy) were similar. CONCLUSIONS: Nonadherence with antidepressant therapy in anxiety disorders is common, but mental health specialty care may be associated with improved adherence. Lower medical costs for adherent patients who did not have a change in medication or a titrated dosage offset the increase in pharmacy costs, resulting in total costs (medical plus pharmacy) that were similar to those of nonadherent patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
4. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes.
- Author
-
Cantrell CR, Eaddy MT, Shah MB, Regan TS, and Sokol MC
- Abstract
OBJECTIVE: The objective of this study was to differentiate between 3 measures of antidepressant adherence with regard to the number of patients deemed adherent to therapy and the association between adherence and resource utilization. DESIGN AND SETTING: The authors conducted a retrospective study of patients initiating selective serotonin reuptake inhibitor (SSRI) therapy for depression and/or anxiety between July 2001 and June 2002 in a large national managed care database. MAIN OUTCOME MEASURES: Rates of 6-month SSRI adherence were measured by 3 different metrics: length of therapy (LOT), medication possession ratio (MPR), and combined MPR/LOT. Differences in resource utilization for each adherence metric were measured for patients deemed as 1) adherent, 2) nonadherent, 3) therapy changers, and 4) dose titraters. RESULTS: There were 22,947 patients meeting study criteria. Although statistically different, 6-month adherence rates were numerically similar across all methods (LOT, 44.6%; MPR, 43.3%; and MPR/LOT, 42.9%, P < 0.001); approximately 57% of patients were nonadherent to therapy. Regardless of metric, the adherent cohort incurred the lowest yearly medical costs, followed by the nonadherent, titrate, and therapy change cohorts (P < 0.001 between adherent cohort and all other cohorts). The LOT method produced the greatest difference in yearly medical costs between adherent and nonadherent patients (Dollars 511) followed by MPR/LOT (Dollars 432) and MPR (Dollars 423). When antidepressant prescription costs were added to medical costs, patients requiring a therapy change and titrating therapy incurred higher costs than adherent patients, whereas nonadherent and adherent patients incurred similar costs. CONCLUSION: Regardless of adherence metric, approximately 43% of patients were adherent to antidepressant therapy, and adherent patients were associated with the lowest yearly medical costs. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
5. Evolving Employer-Sponsored Health Care Toward a Post-COVID-19 Marketplace.
- Author
-
Sokol MC
- Subjects
- Delivery of Health Care, Humans, Insurance Coverage, SARS-CoV-2, United States, COVID-19, Health Benefit Plans, Employee
- Published
- 2021
- Full Text
- View/download PDF
6. Evidence that value-based insurance can be effective.
- Author
-
Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, Sokol MC, Yu-Isenberg K, and Fendrick AM
- Subjects
- Chronic Disease drug therapy, Cost Sharing, Costs and Cost Analysis, Humans, Patient Acceptance of Health Care psychology, Prescription Drugs economics, Prescription Drugs supply & distribution, Reimbursement Mechanisms, United States, Deductibles and Coinsurance, Evidence-Based Practice, Health Benefit Plans, Employee economics, Health Care Costs, Health Expenditures statistics & numerical data, Health Expenditures trends, Health Plan Implementation, Program Evaluation economics
- Abstract
Value-based insurance design reduces patient copayments to encourage the use of health care services of high clinical value. As employers face constant pressure to control health care costs, this type of coverage has received much attention as a cost-savings device. This paper's examination of one value-based insurance design program found that the program led to reduced use of nondrug health care services, offsetting the costs associated with additional use of drugs encouraged by the program. The findings suggest that value-based insurance design programs do not increase total systemwide medical spending.
- Published
- 2010
- Full Text
- View/download PDF
7. Effects of increased patient cost sharing on socioeconomic disparities in health care.
- Author
-
Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, and Fendrick AM
- Subjects
- Comorbidity, Fees, Pharmaceutical, Female, Humans, Income statistics & numerical data, Linear Models, Male, Medication Adherence, United States, Cost Sharing economics, Diabetes Mellitus drug therapy, Drug Costs, Drug Prescriptions economics, Health Expenditures, Health Status Disparities, Heart Failure drug therapy
- Abstract
Background: Increasing patient cost sharing is a commonly employed mechanism to contain health care expenditures., Objective: To explore whether the impact of increases in prescription drug copayments differs between high- and low-income areas., Design: Using a database of 6 million enrollees with employer-sponsored health insurance, econometric models were used to examine the relationship between changes in drug copayments and adherence with medications for the treatment of diabetes mellitus (DM) and congestive heart failure (CHF)., Subjects: Individuals 18 years of age and older meeting prespecified diagnostic criteria for DM or CHF were included., Measurements: Median household income in the patient's ZIP code of residence from the 2000 Census was used as the measure of income. Adherence was measured by medication possession ratio: the proportion of days on which a patient had a medication available., Results: Patients in low-income areas were more sensitive to copayment changes than patients in high- or middle-income areas. The relationship between income and price sensitivity was particularly strong for CHF patients. Above the lowest income category, price responsiveness to copayment rates was not consistently related to income., Conclusions: The relationship between medication adherence and income may account for a portion of the observed disparities in health across socioeconomic groups. Rising copayments may worsen disparities and adversely affect health, particularly among patients living in low-income areas.
- Published
- 2008
- Full Text
- View/download PDF
8. Impact of decreasing copayments on medication adherence within a disease management environment.
- Author
-
Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, and Fendrick AM
- Subjects
- Adult, Aged, Anticholesteremic Agents therapeutic use, Cohort Studies, Cross-Sectional Studies, Databases, Factual, Female, Humans, Male, Middle Aged, United States, Anticholesteremic Agents economics, Cost Sharing, Disease Management, Health Benefit Plans, Employee economics, Patient Compliance statistics & numerical data
- Abstract
This paper estimates the effects of a large employer's value-based insurance initiative designed to improve adherence to recommended treatment regimens. The intervention reduced copayments for five chronic medication classes in the context of a disease management (DM) program. Compared to a control employer that used the same DM program, adherence to medications in the value-based intervention increased for four of five medication classes, reducing nonadherence by 7-14 percent. The results demonstrate the potential for copayment reductions for highly valued services to increase medication adherence above the effects of existing DM programs.
- Published
- 2008
- Full Text
- View/download PDF
9. Impact of antidepressant drug adherence on comorbid medication use and resource utilization.
- Author
-
Katon W, Cantrell CR, Sokol MC, Chiao E, and Gdovin JM
- Subjects
- Antidepressive Agents economics, Coronary Disease economics, Depression complications, Dyslipidemias economics, Female, Health Care Costs, Humans, Male, Middle Aged, Retrospective Studies, United States, Antidepressive Agents therapeutic use, Coronary Disease complications, Depression drug therapy, Diabetes Mellitus economics, Drug Utilization Review, Dyslipidemias complications, Patient Compliance
- Abstract
Background: Patients with depression are often nonadherent to therapy for depression and chronic comorbid conditions., Methods: To determine whether improved antidepressant medication adherence is associated with an increased likelihood of chronic comorbid disease medication adherence and reduced medical costs, we conducted a retrospective study of patients initiating antidepressant drug therapy with evidence of dyslipidemia, coronary artery disease (CAD), or both; diabetes mellitus (DM); or CAD/dyslipidemia and DM identified from a claims database. Measures included antidepressant medication adherence, measured by medication possession ratio during 180 days without a 15-day gap before 90 days of therapy; comorbid medication adherence, measured by medication possession ratio during 1 year; and the association between improved antidepressant drug adherence and disease-specific and total medical costs., Results: Of 8040 patients meeting the study criteria, those adherent to antidepressant medication were more likely to be adherent to comorbid therapy vs those nonadherent to antidepressant drug therapy (CAD/dyslipidemia: odds ratio [OR], 2.13; DM: OR, 1.82; and CAD/dyslipidemia/DM: OR, 1.45; P<.001 for all). Patients adherent to antidepressant drug therapy also had significantly lower disease-specific charges vs nonadherent patients (17% lower in CAD/dyslipidemia, P = .02; 8% lower in DM, P = .39; and 14% lower in CAD/dyslipidemia/DM, P = .38). These patients also incurred lower total medical charges (6.4% lower in CAD/dyslipidemia, P = .048; 11.8% lower in DM, P = .04; and 19.8% lower in CAD/dyslipidemia/DM, P = .03)., Conclusions: Antidepressant drug adherence was associated with increased comorbid disease medication adherence and reduced total medical costs for CAD/dyslipidemia, DM, and CAD/dyslipidemia/DM. Future studies should investigate the relationship between increased adherence and costs beyond 1 year.
- Published
- 2005
- Full Text
- View/download PDF
10. Impact of medication adherence on hospitalization risk and healthcare cost.
- Author
-
Sokol MC, McGuigan KA, Verbrugge RR, and Epstein RS
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Chronic Disease economics, Cohort Studies, Comorbidity, Drug Prescriptions, Health Services economics, Health Services statistics & numerical data, Hospitalization economics, Humans, Infant, Infant, Newborn, Insurance, Pharmaceutical Services, Linear Models, Middle Aged, Retrospective Studies, Self Administration economics, Treatment Outcome, United States, Chronic Disease drug therapy, Health Care Costs statistics & numerical data, Hospitalization statistics & numerical data, Patient Compliance statistics & numerical data, Self Administration statistics & numerical data
- Abstract
Objective: The objective of this study was to evaluate the impact of medication adherence on healthcare utilization and cost for 4 chronic conditions that are major drivers of drug spending: diabetes, hypertension, hypercholesterolemia, and congestive heart failure., Research Design: The authors conducted a retrospective cohort observation of patients who were continuously enrolled in medical and prescription benefit plans from June 1997 through May 1999. Patients were identified for disease-specific analysis based on claims for outpatient, emergency room, or inpatient services during the first 12 months of the study. Using an integrated analysis of administrative claims data, medical and drug utilization were measured during the 12-month period after patient identification. Medication adherence was defined by days' supply of maintenance medications for each condition., Patients: The study consisted of a population-based sample of 137,277 patients under age 65., Measures: Disease-related and all-cause medical costs, drug costs, and hospitalization risk were measured. Using regression analysis, these measures were modeled at varying levels of medication adherence., Results: For diabetes and hypercholesterolemia, a high level of medication adherence was associated with lower disease-related medical costs. For these conditions, higher medication costs were more than offset by medical cost reductions, producing a net reduction in overall healthcare costs. For diabetes, hypercholesterolemia, and hypertension, cost offsets were observed for all-cause medical costs at high levels of medication adherence. For all 4 conditions, hospitalization rates were significantly lower for patients with high medication adherence., Conclusions: For some chronic conditions, increased drug utilization can provide a net economic return when it is driven by improved adherence with guidelines-based therapy.
- Published
- 2005
- Full Text
- View/download PDF
11. Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.
- Author
-
Sokol MC
- Subjects
- Etanercept, Health Services Accessibility, Humans, Infliximab, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal economics, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents administration & dosage, Antirheumatic Agents economics, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Immunoglobulin G administration & dosage, Immunoglobulin G economics, Immunoglobulin G therapeutic use, Insurance Coverage organization & administration, Receptors, Tumor Necrosis Factor administration & dosage, Receptors, Tumor Necrosis Factor therapeutic use, Reimbursement Mechanisms
- Abstract
Early and aggressive treatment of rheumatoid arthritis (RA) can provide cost savings through enhanced and sustained clinical outcomes. Antitumor necrosis factor-alpha (anti-TNF) agents, such as infliximab and etanercept, provide a superior level of clinical benefit, particularly in patients with moderate-to-severe RA. Reimbursement of these agents falls under either a pharmacy or medical benefit, depending on their route of administration. However, inconsistencies in reimbursement strategies across plans potentially restrict clinician and patient access to these safe and effective therapies. Benefits should be designed to ensure that all eligible patients have access to anti-TNF agents, with the understanding that earlier treatment of RA with safe and effective agents provides significant cost savings to future insurers through enhanced and sustained outcomes.
- Published
- 2005
12. Chemical ablation of the gallbladder: evaluation of multiple agents in vitro.
- Author
-
Soulen MC, Sokol MC, and Sullivan KL
- Subjects
- Animals, Ethanol pharmacology, Hydrogen Peroxide pharmacology, In Vitro Techniques, Sodium Hydroxide pharmacology, Swine, Gallbladder drug effects, Sclerosing Solutions pharmacology
- Abstract
Purpose: To find a more effective chemical regimen for transcatheter ablation of the gallbladder in an in vitro model., Materials and Methods: Sectioned and whole pig gallbladders were exposed in vitro to 12 different chemical solutions at varying conditions of exposure time, pH, and temperature., Results: In the in vitro studies, 0.1 N and 1.0 N solutions of sodium hydroxide in water or ethanol and 3% hydrogen peroxide were the most effective sclerosant agents. Ethanol and hydrochloric acid failed to completely eliminate the epithelium from the gallbladder sections. Increasing exposure time from 10 to 20 minutes or increasing the temperature of the solutions from 37 degrees C to 50 degrees C did not alter these results. Sequential 15-minute exposures to 0.1 N sodium hydroxide in ethanol followed by peroxide completely eliminated the epithelium from whole gallbladders in vitro., Conclusion: Alkaline solutions and hydrogen peroxide are more effective than ethanol alone, acids, or detergents in eliminating gallbladder epithelium in this model. Further evaluation of these agents in vivo is merited.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.